Strontium chloride

Strontium chloride Overview

Strontium chloride (chemically designated as strontium dichloride; chemical formula SrCl2) is an inorganic alkaline earth metal salt. Chemically, it belongs to the class of inorganic compounds known as alkaline earth metal chlorides. Structurally, it consists of a central divalent strontium cation (Sr2+) ionically bonded to two chloride anions (Cl-). In its radiotherapeutic formulation, the strontium atom is substituted with the beta-emitting radioisotope Strontium-89 (Sr-89).

In oncologic nuclear medicine, palliative care, and nephrology, Strontium chloride functions as a bone-seeking therapeutic radiopharmaceutical and palliative antineoplastic agent (ATC code V10BX01 for therapeutic radiopharmaceuticals). Formulated as sterile aqueous solutions for intravenous injection (marketed under the trade name Metastron containing strontium chloride Sr-89), it is indicated for the palliative treatment of painful skeletal metastases resulting from advanced malignancies, particularly castrate-resistant prostate cancer and breast cancer with blastic or sclerotic bone involvement. Because strontium shares chemical and biological properties with calcium, it selectively targets and incorporates into areas of active osteogenesis and high bone mineral turnover. Additionally, non-radioactive strontium chloride formulations were historically incorporated into topical dental pastes and gels (e.g., Lorvic Desensitizer) to treat dentinal hypersensitivity by occluding exposed dentinal tubules, though this application has largely been replaced by modern nerve-calming agents.

What Is Strontium chloride and How Does It Work?

Strontium chloride acts primarily through calcium-mimetic selective accumulation in active osteoblastic bone metastases, delivering localized beta-radiation to suppress pain signals and reduce metastatic lesion activity.

Its primary chemical, physiological, and radiotherapeutic mechanisms include:

• Calcium-Mimetic Bone Seeking: As a divalent alkaline earth cation, Sr2+ chemically mimics calcium (Ca2+) in vivo. Following intravenous administration, it rapidly concentrates at sites of high bone mineral turnover, selectively depositing within the hydroxyapatite matrix of osteoblastic and sclerotic bone metastases.
• Selective Metastatic Retention: While strontium in normal cortical and trabecular bone turns over with a biological half-life of approximately 14 days, it is retained within metastatic bone lesions for prolonged periods exceeding the physical half-life of the Sr-89 isotope (50.5 days).
• Targeted Beta Radiation Emission: Strontium-89 decays by emitting pure high-energy beta particles (maximum energy 1.463 MeV) with a maximum tissue penetration range of 6 to 8 mm. This localized radiation selectively destroys nerve endings in the periosteum, suppresses local osteoclast and tumor cell activity, reduces inflammatory cytokine release, and relieves metastatic bone pain while sparing surrounding soft tissues.
• Renal Elimination Dynamics: In healthy individuals, approximately 75% of an administered dose is excreted renally. In patients with extensive skeletal metastases, up to 90% of the radioactive dose is retained in metastatic bone, decreasing urinary clearance and prolonging systemic clearance times.
• Dentinal Tubule Occlusion (Topical Action): When applied topically to exposed dentin, strontium ions precipitate within microscopic dentinal tubules, blocking fluid movement and mechanical stimulus transmission to underlying pulp nerves.

Is Strontium chloride FDA Approved?

Strontium chloride Sr-89 was approved by the US FDA in June 1993 under the brand name Metastron. Its current approval status is FDA Approved (June 1993).

What Is Strontium chloride Used For?

• Palliative management of severe, painful skeletal metastases in patients with advanced prostate cancer or breast cancer confirmed by bone scintigraphy.
• Reduction of opioid analgesic requirements in patients with widespread, painful metastatic bone disease.
• Historical over-the-counter and professional topical treatment of dentinal teeth hypersensitivity.

Before Taking Strontium chloride: Contraindications & Precautions

Do not administer radiopharmaceutical Strontium chloride Sr-89 to patients with severe baseline bone marrow suppression (platelet counts below 60,000/mcL or absolute neutrophil counts below 1,300/mcL). Avoid in patients with acute spinal cord compression due to epidural metastases requiring immediate surgical or external beam radiation decompression. Exercise extreme caution in patients with severe renal impairment, as decreased glomerular filtration delays radiopharmaceutical excretion, increasing whole-body radiation exposure.

Who Should Not Take Strontium chloride?

• Patients with severe bone marrow failure, marked leukopenia, or severe thrombocytopenia.
• Individuals with known hypersensitivity to strontium chloride or formulation components.
• Pregnant or breastfeeding women.
• Patients requiring rapid emergency decompression for spinal cord compression.

Strontium chloride, Pregnancy & Safety

Strontium chloride Sr-89 is a radioactive agent that causes direct fetal harm when administered to pregnant women. Systemic radioactive beta emission disrupts embryonic and fetal cellular development, inducing teratogenicity, severe growth retardation, and fetal death. Female patients of reproductive potential must undergo pregnancy testing prior to administration and use effective contraception during treatment and for at least 6 months post-injection. Male patients with female partners of reproductive potential must use effective barrier contraception for 6 months following administration. Breastfeeding is strictly contraindicated due to radioactive excretion in breast milk.

Tell Your Doctor Before Taking Strontium doctor

Inform your oncologist, nuclear medicine physician, or nephrologist if you have a history of low blood cell counts, easy bruising, active infection, severe kidney disease, urinary incontinence, or prior extensive pelvic or total-body external beam radiation therapy.

Strontium chloride Dosage & Administration

Formulated as a sterile, clear, colorless aqueous solution for intravenous injection containing 1 mCi/mL (37 MBq/mL) of Strontium-89 chloride.

Standard Strontium chloride Dosing

• Palliative Bone Pain Administration (Adults): The standard recommended intravenous dose is 148 MBq (4.0 mCi), or 1.5 to 2.2 MBq/kg (40 to 60 uCi/kg) of body weight. Repeat administrations should not be considered within 12 weeks (3 months) of the previous dose and require full hematologic recovery.

How Strontium chloride Is Administered

• Administered strictly via slow intravenous injection over 1 to 2 minutes by licensed nuclear medicine personnel in an outpatient radioisotope facility.
• Ensure adequate oral hydration before and after injection to encourage frequent voiding and accelerate urinary excretion of unabsorbed radiopharmaceutical.

Strontium chloride Clinical Efficacy & Safety Profile

Pivotal clinical trials establish that a single intravenous dose of Strontium chloride Sr-89 produces significant bone pain reduction in 75% to 80% of treated patients with metastatic prostate or breast cancer, with complete pain relief achieved in up to 20% to 30% of cases. Analgesic response typically begins within 7 to 20 days post-injection and lasts for a median duration of 3 to 6 months. Addition of Strontium-89 to external beam radiotherapy significantly reduces the emergence of new metastatic bone pain sites. However, its primary dose-limiting toxicity is myelosuppression, requiring weekly monitoring of peripheral blood counts.

Strontium chloride Side Effects & Safety Profile

Common adverse effects include transient increase in bone pain (“pain flare”) occurring within the first 2 to 3 days post-injection, mild nausea, flushing, and transient fever. Serious adverse risks include severe, prolonged myelosuppression (thrombocytopenia and leukopenia), increased risk of serious systemic infections, bleeding complications, and acute renal radiation overload in patients with impaired clearance. Holds no FDA Black Box Warning.

Common Strontium chloride Side Effects

• Transient Flare & Systemic: Temporary increase in metastatic bone pain (“pain flare”) lasting 24 to 72 hours, warm flushing sensation during injection, mild nausea, and low-grade fever.

Serious Strontium chloride Adverse Events

• Bone Marrow Suppression (Myelosuppression): Significant drop in blood cell counts; platelet counts typically decline to a nadir at 4 to 6 weeks post-injection (averaging a 20% to 30% reduction), with leukopenia increasing susceptibility to severe infections.
• Bleeding & Hemorrhage: Severe thrombocytopenia leading to cutaneous petechiae, easy bruising, epistaxis, or gastrointestinal hemorrhage.
• Renal Accumulation & Radiation Exposure: In patients with renal failure, delayed urinary elimination increases red marrow and soft tissue absorbed radiation doses.

Managing Strontium chloride Side Effects

Manage transient pain flares with short-term increases in non-opioid or opioid analgesics. Monitor complete blood counts weekly for at least 8 to 12 weeks post-dose. Withhold further myelosuppressive chemotherapy or repeat radionuclide therapy until platelet and leukocyte counts recover fully.

Strontium chloride Drug Interactions & What to Avoid

Co-administration with myelosuppressive or calcium-containing medications requires specific clinical precautions.

Strontium chloride Drug-Drug Interactions

• Bone Marrow Suppressive Agents (e.g., Carboplatin, Docetaxel, Cyclophosphamide): Concomitant administration with cytotoxic chemotherapy markedly increases the risk of severe, irreversible neutropenia and thrombocytopenia.
• Calcium Supplements & Hypercalcemia Treatments: High doses of oral or intravenous calcium compete with strontium for osteoblastic skeletal binding sites, significantly reducing Strontium-89 bone uptake and therapeutic efficacy.

Strontium chloride, Food & Alcohol

Systemic intravenous administration is unaffected by food intake. Ensure high daily oral fluid intake to facilitate renal excretion of unabsorbed radioactivity.

Strontium chloride: Missed Dose, Overdose & Storage

Administered as a single scheduled nuclear medicine procedure. Overdose increases radiation burden and myelosuppression. Store in a shielded container at room temperature (15°C–25°C).

Missed Dose of Strontium chloride

Not applicable; administered as a single, scheduled therapeutic radiopharmaceutical procedure by nuclear medicine specialists.

Strontium chloride Overdose & Emergency

Accidental radiopharmaceutical overdose leads to severe, prolonged bone marrow aplasia, complete pancytopenia, bleeding complications, and overwhelming systemic infection. Emergency management involves isolation, blood product transfusions (platelets and packed red blood cells), hematopoietic growth factors (G-CSF), and aggressive broad-spectrum intravenous antibiotic therapy.

How to Store Strontium chloride

Store the radiopharmaceutical vial at controlled room temperature between 15°C and 25°C (59°F to 77°F) inside its lead shielding container. Radioactivity must be handled, stored, and disposed of in strict accordance with federal and state radiation control regulations. Keep strictly out of reach of children.

Strontium chloride Patient Management & Monitoring

Requires strict radiation safety precautions, weekly blood count tracking, and renal function monitoring.

Tests Before Starting Strontium chloride

Baseline diagnostic bone scan (scintigraphy) confirming osteoblastic bone metastases, complete blood count (CBC with differential and platelet count), serum creatinine, estimated glomerular filtration rate (eGFR), and baseline liver function tests.

Monitoring During Strontium chloride Treatment

Weekly complete blood count monitoring for at least 8 to 12 weeks post-injection to track platelet and white blood cell nadirs; monitoring urinary output; checking for signs of bleeding or infection.

Strontium chloride Do’s and Don’ts

• Do drink plenty of fluids for several days following the injection to flush unabsorbed radiation through the kidneys.
• Do practice strict hygiene (double flushing the toilet, washing hands thoroughly, sitting while urinating) for 1 to 2 weeks post-injection to prevent radioactive contamination of family members.
• Do report signs of infection (fever, sore throat) or unusual bleeding/bruising to your doctor immediately.
  Australian Commission on Safety and Quality in Health Care
• Do not undergo repeat Strontium-89 therapy within 12 weeks of a prior dose.
• Do not take calcium supplements immediately before or during therapy without nuclear medicine guidance.

Frequently Asked Questions

References

• DrugBank Database – Strontium Chloride Clinical Profile (DB13987)
• Classyfire Database – Alkaline Earth Metal Chlorides / Inorganic Compounds Taxonomy Profile
• US FDA Prescribing Information – Metastron (Strontium-89 Chloride) Injection

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.